Oxford Vacmedix UK Analysis: $20M Raised
What is Oxford Vacmedix UK?
Immunotherapy using recombinant overlapping peptides
Location
Oxford, United Kingdom
Employees
1-10
Founded
2012
Product Features & Capabilities
- OVM-200
- OVM-100
- OVM-400
- AMR Diagnostic
Use Cases
Treat advanced non-small cell lung cancer; Treat ovarian cancer; Treat prostate cancer; Develop mRNA delivery systems; Conduct Phase 1 and Phase 2 clinical trials
How much Oxford Vacmedix UK raised
Funding - $20M
Other Considerations
Seeking Series B investment for clinical trials; Ongoing Phase 1 trial with strong preliminary data; Spinout from the University of Oxford
See something that needs updating? Suggest edits to this profile.